November 22, 2024
Breakthrough T1D, Formerly JDRF, Statement on FDA Decision Not to Approve Zynquista (sotagliflozin) for Glucose Control in People with Type 1 Diabetes and Chronic Kidney Disease
November 18, 2024
Breakthrough T1D Applauds Senate Diabetes Caucus Co-Chairs for Leading Bipartisan Letter of Support for Special Diabetes Program
November 15, 2024
Breakthrough T1D Leads Effort to Make Screening for T1D Part of Recommended Preventive Services in the US
November 14, 2024
Breakthrough T1D Mourns the Passing of Five T1D Champions
November 14, 2024
Type 1 Diabetes Community Celebrates Research Milestone During National Diabetes Month
November 14, 2024
Breakthrough T1D Recognizes World Diabetes Day with the Announcement of Project ACT
November 7, 2024
Breakthrough T1D, Lupus Research Alliance, and the National Multiple Sclerosis Society Seek Applications from Investigators to Advance the Understanding of Autoimmunity
November 4, 2024
Breakthrough T1D, Formerly JDRF, Celebrates Progress in Cell Therapy Research on the Path to Type 1 Diabetes Cures as Vertex Announces Pivotal Trial for VX-880
October 31, 2024
Breakthrough T1D, Formerly JDRF, Expresses Disappointment in FDA Advisory Committee Recommendation Regarding Sotagliflozin
October 29, 2024
